VEGFA and glioblastoma: Nonetheless, one of the most recent drugs approved for glioblastoma, bevacizumab, is a monoclonal antibody blocking the vascular endothelial growth factor (VEGF), which did not improve overall survival in unselected patients and led to a reduction in temozolomide delivery, altering the vascular remodeling [53].